Molecular subtypes and local-regional control of breast cancer
SM Fragomeni, A Sciallis… - Surgical Oncology …, 2018 - surgonc.theclinics.com
Breast cancer is a heterogeneous disease that affects one anatomic site, yet is
phenotypically variable. 1, 2 The identification of different biological subtypes occurs …
phenotypically variable. 1, 2 The identification of different biological subtypes occurs …
[HTML][HTML] Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments
TC Gillespie, HE Sayegh, CL Brunelle, KM Daniell… - Gland …, 2018 - ncbi.nlm.nih.gov
Breast cancer-related lymphedema (BCRL) is a negative sequela of breast cancer
treatment, and well-established risk factors include axillary lymph node dissection (ALND) …
treatment, and well-established risk factors include axillary lymph node dissection (ALND) …
Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology
WJ Gradishar, MS Moran, J Abraham, R Aft… - Journal of the National …, 2022 - jnccn.org
The therapeutic options for patients with noninvasive or invasive breast cancer are complex
and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include …
and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include …
Management of the axilla in early-stage breast cancer: Ontario Health (Cancer Care Ontario) and ASCO guideline
M Brackstone, FG Baldassarre, FE Perera… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To provide recommendations on the best strategies for the management and on
the best timing and treatment (surgical and radiotherapeutic) of the axilla for patients with …
the best timing and treatment (surgical and radiotherapeutic) of the axilla for patients with …
Omitting axillary dissection in breast cancer with sentinel-node metastases
J de Boniface, T Filtenborg Tvedskov… - … England Journal of …, 2024 - Mass Medical Soc
Background Trials evaluating the omission of completion axillary-lymph-node dissection in
patients with clinically node-negative breast cancer and sentinel-lymph-node metastases …
patients with clinically node-negative breast cancer and sentinel-lymph-node metastases …
Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG …
AE Giuliano, KV Ballman, L McCall, PD Beitsch… - Jama, 2017 - jamanetwork.com
Importance The results of the American College of Surgeons Oncology Group Z0011
(ACOSOG Z0011) trial were first reported in 2005 with a median follow-up of 6.3 years …
(ACOSOG Z0011) trial were first reported in 2005 with a median follow-up of 6.3 years …
Preservation of axillary lymph nodes compared with complete dissection in T1–2 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the …
C Tinterri, D Gentile, W Gatzemeier, A Sagona… - Annals of surgical …, 2022 - Springer
Abstract Background The SINODAR-ONE trial is a prospective noninferiority multicenter
randomized study aimed at assessing the role of axillary lymph node dissection (ALND) in …
randomized study aimed at assessing the role of axillary lymph node dissection (ALND) in …
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 …
M Donker, G van Tienhoven, ME Straver… - The lancet …, 2014 - thelancet.com
Background If treatment of the axilla is indicated in patients with breast cancer who have a
positive sentinel node, axillary lymph node dissection is the present standard. Although …
positive sentinel node, axillary lymph node dissection is the present standard. Although …
Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up …
AE Giuliano, K Ballman, L McCall, P Beitsch… - Annals of …, 2016 - journals.lww.com
Methods: ACOSOG Z0011 prospectively examined overall survival of patients with SLN
metastases undergoing breast-conserving therapy randomized to undergo ALND after …
metastases undergoing breast-conserving therapy randomized to undergo ALND after …
NCCN guidelines insights: breast cancer, version 1.2017
WJ Gradishar, BO Anderson, R Balassanian… - Journal of the national …, 2017 - jnccn.org
These NCCN Guidelines Insights highlight the important updates/changes to the surgical
axillary staging, radiation therapy, and systemic therapy recommendations for hormone …
axillary staging, radiation therapy, and systemic therapy recommendations for hormone …